Newsfeed : AHF Campaigns Against PrEP as a 'Public Health Intervention'

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Newsfeed » August 2014

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ


More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

August 25, 2014

AHF Campaigns Against PrEP as a 'Public Health Intervention'

The AIDS Healthcare Foundation (AHF) has launched an advertising campaign against using the HIV drug Truvada as a public health intervention for pre-exposure prophylaxis (PrEP) to prevent transmission of the virus, according to an AHF statement. The group claims that current PrEP data do not support such use.

“The eight major studies show the scientific data do not support the large-scale use of Truvada as a community-wide public health intervention to prevent transmission of HIV,” said AHF president Michael Weinstein in the statement. His concern is medication adherence, which he claims the data shows is poor.

PrEP adherence has been explored by several studies with varying results. However, the growing consensus is that on a personal level the data shows that PrEP is highly effective for individuals when taken as directed. The AHF statement cautions against PrEP as a public health policy, but does not directly address that consensus.

In 2012, the U.S. Food and Drug Administration (FDA) approved Truvada for PrEP. In 2014, the U.S. Centers for Disease Control and Prevention (CDC), as well as the World Health Organization (WHO), issued PrEP recommendations. AHF claims both the CDC and the WHO issued “misguided” recommendations.

The “PrEP Facts” campaign is appearing in various outlets in California and Florida throughout August and will likely expand to other markets. According to AHF, the ads not only caution against widespread scale up of PrEP, but also “educate the public as to the critical, but complicated role” of adherence.

To read the statement, click here.

Search: AHF, PrEP, prevention, adherence, FDA, CDC, WHO


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (26 total)

 
[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.